Novavax (NVAX) Tops Q1 EPS by 18c; offers guidance

Novavax (NASDAQ: NVAX) reported Q1 EPS of ($0.06), $0.18 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $139.51 million versus the consensus estimate of $79.31 million.

GUIDANCE:

Novavax sees FY2026 revenue of $230-270 million, versus the consensus of $394.3 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• Trump: Scott Bessent will not be going to be super intelligence (SI) czar
• ISS backs two ATG Capital nominees for Empery Digital board
• Raymond James: 'Within fiberglass, the ski/wake segment (relevant for Malibu and MasterCraft) fell 18.2% y/y (-8.1% YTD)'